DR. PATRICIA KILROY DONAHOE, MD
Radiology at Fruit St, Boston, MA
License number
Massachusetts 29158
Category
Radiology
Type
Surgery
License number
Massachusetts 29158
Category
Radiology
Type
Pediatric Surgery
Address
Address
55 Fruit St, Boston, MA 02114
Phone
(617) 726-8839
(617) 726-2167 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
(617) 726-2167 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
Personal information
See more information about PATRICIA KILROY DONAHOE at radaris.comName
Address
Phone
8 Whittier Pl APT 16H, Boston, MA 02114
5 Rita Rd, Peabody, MA 01960
17 Maple Ave, Everett, MA 02149
Hyannis, MA
Professional information
Dr. Patricia K Donahoe, Boston MA - MD (Doctor of Medicine)
Specialties:
Pediatric Surgery
Address:
55 Fruit St, Boston 02114
(617) 726-8839 (Phone), (617) 726-2167 (Fax)
(617) 726-8839 (Phone), (617) 726-2167 (Fax)
Certifications:
General Surgery, 1971, Pediatric Surgery, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
55 Fruit St, Boston 02114
Massachusetts General Hospital
55 Fruit St, Boston 02114
Massachusetts General Hospital
55 Fruit St, Boston 02114
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1964
Tufts-New England Ctr Hosp
Childrens Hospital
Massachusetts General Hospital
Alder Rey Children's Hospital Eng
Children's Hospital Harvard
Mass General Hospital Harvard
Columbia University / College of Physicians And Surgeons
Graduated: 1964
Tufts-New England Ctr Hosp
Childrens Hospital
Massachusetts General Hospital
Alder Rey Children's Hospital Eng
Children's Hospital Harvard
Mass General Hospital Harvard
Patricia Kilroy Donahoe, Boston MA
Specialties:
Urology, Pediatric Urology, Pediatrics, Surgery, Pediatric Surgery, Pediatric Neurological Surgery
Work:
Massachusetts General Hospital
55 Fruit St, Boston, MA 02114
55 Fruit St, Boston, MA 02114
Education:
Columbia University (1964)
Patricia Kilroy Donahoe, Boston MA
Specialties:
Surgeon
Address:
55 Fruit St, Boston, MA 02114
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine*
Massachusetts General Hospital - Residency - Pediatric Surgery (General Surgery)*
Children's Hospital Boston - Residency - Pediatric Surgery (General Surgery)*
Massachusetts General Hospital - Residency - Pediatric Surgery (General Surgery)*
Children's Hospital Boston - Residency - Pediatric Surgery (General Surgery)*
Board certifications:
American Board of Surgery Certification in Surgery*
Delivery Of Therapeutic Biologicals From Implantable Tissue Matrices
US Patent:
6692738, Feb 17, 2004
Filed:
Jan 26, 2001
Appl. No.:
09/770339
Inventors:
David T. MacLaughlin - Saugus MA
Joseph P. Vacanti - Winchester MA
Patricia K. Donahoe - Boston MA
Peter T. Masiakos - Boston MA
Joseph P. Vacanti - Winchester MA
Patricia K. Donahoe - Boston MA
Peter T. Masiakos - Boston MA
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 4800
US Classification:
424 9321, 424484, 435455, 435325
Abstract:
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptinâ¢, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.
Use Of Mullerian Inhibiting Substance For Treating Excess Androgen States
US Patent:
6673352, Jan 6, 2004
Filed:
Sep 14, 2000
Appl. No.:
09/662341
Inventors:
Patricia K. Donahoe - Boston MA
Jose Teixeira - Boston MA
Eric Fynn-Thompson - Boston MA
Jose Teixeira - Boston MA
Eric Fynn-Thompson - Boston MA
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 3900
US Classification:
4241981, 435 721, 530350, 530324, 514 2
Abstract:
The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The present invention also provides a method of decreasing the level of one or more androgens to a level below the normal level, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The methods of the present invention are particularly well-suited for the treatment of prostatic cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.
Pyrazoloanthrone And Derivatives Thereof For The Treatment Of Cancer Expressing 'Mullerian Inhibiting Substance' Type Ii Receptor (Misrii) And Of Excess Androgen States
US Patent:
2010023, Sep 16, 2010
Filed:
Mar 21, 2008
Appl. No.:
12/532533
Inventors:
Jose Teixeira - Boston MA, US
Patricia K Donahoe - Boston MA, US
Patricia K Donahoe - Boston MA, US
Assignee:
THE GENERAL HOSPITAL CORPORATION - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel.
Pyrazoloanthrone And Derivatives Thereof For Treatment Of Cancer And Excess Androgen States
US Patent:
2012014, Jun 7, 2012
Filed:
Dec 16, 2011
Appl. No.:
13/328387
Inventors:
Jose Teixeira - Boston MA, US
Patricia K. Donahoe - Boston MA, US
Patricia K. Donahoe - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 31/416, A61P 35/00, A61K 38/22, A61K 33/24, A61K 31/704, A61K 31/436
US Classification:
424649, 514406, 514 34, 514291, 514 97
Abstract:
Provided herein are pyrazoloanthrones or functional derivatives or analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, methods are provided to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or analogue thereof. Also provided herein are methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or analogue thereof. Also provided are methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or analogue thereof that lowers the effective dose of the chemotherapeutic agent.
Methods To Identify And Enrich For Populations Of Ovarian Cancer Stem Cells And Somatic Ovarian Stem Cells And Uses Thereof
US Patent:
2010027, Oct 28, 2010
Filed:
Jul 17, 2008
Appl. No.:
12/669136
Inventors:
Patricia K. Donahoe - Boston MA, US
Paul P. Szotek - Indianapolis IN, US
David T. MacLaughlin - Gloucester MA, US
Frederic Preffer - Cambridge MA, US
David Michael Dombkowski - Cambridge MA, US
Paul P. Szotek - Indianapolis IN, US
David T. MacLaughlin - Gloucester MA, US
Frederic Preffer - Cambridge MA, US
David Michael Dombkowski - Cambridge MA, US
Assignee:
THE GENERAL HOSPITAL CORPORATION - Boston MA
International Classification:
C12Q 1/04, C12N 5/09, C12Q 1/02, C12Q 1/68
US Classification:
435 6, 435366, 435 34, 435 29
Abstract:
The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.
Use Of Mullerian Inhibiting Substance And Interferon For Treating Tumors
US Patent:
2004015, Aug 5, 2004
Filed:
Aug 25, 2003
Appl. No.:
10/646784
Inventors:
Shyamala Maheswaran - Lexington MA, US
Patricia Donahoe - Boston MA, US
Patricia Donahoe - Boston MA, US
Assignee:
The General Hospital Corporation
International Classification:
A61K038/21, A61K038/17
US Classification:
424/085400, 514/012000
Abstract:
The present invention is directed to a method of increasing anti-tumor effect of interferon, the method comprising administering to a patient in need thereof an effective amount of MIS and an effective amount of interferon that results in decreased side-effects, thereby increasing anti-tumor effect of interferon. The invention is also directed to a method of inhibiting growth of tumor, the method comprising administering to a patient an effective amount of MIS and an amount of interferon that results in decreased side-effects. The invention is further directed to a tumor inhibiting pharmaceutical composition comprising an effective tumor inhibiting amount of MIS and interferon, wherein the effective tumor inhibiting amount of interferon is an amount that results in decreased side effects.
Use Of Mullerian Inhibiting Substance For Treating Excess Androgen States
US Patent:
2004006, Apr 1, 2004
Filed:
Oct 10, 2003
Appl. No.:
10/683346
Inventors:
Patricia Donahoe - Boston MA, US
Jose Teixeira - Boston MA, US
Eric Fynn-Thompson - Boston MA, US
Jose Teixeira - Boston MA, US
Eric Fynn-Thompson - Boston MA, US
Assignee:
The General Hospital Corporation
International Classification:
A61K038/19
US Classification:
424/085100
Abstract:
The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The present invention also provides a method of decreasing the level of one or more androgens to a level below the normal level, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The methods of the present invention are particularly well-suited for the treatment of prostatic cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.